This year’s Lasker∼DeBakey Clinical Research Award goes to James Allison for discovering that antibody blockade of the T cell molecule CTLA-4 unleashes the body’s immune response against malignant tumors. This has led to development of multiple “immune checkpoint therapies” that are prolonging and saving the lives of thousands of cancer patients
Immune checkpoints blockade (ICB) has made revolutionary progress in cancer therapy recently. The de...
The past few years have witnessed something of a renaissance in the field of cancer immunotherapy, r...
Tumor immunotherapy has come to the fore fuelled by impressive clinical responses to checkpoint inhi...
This year the Lasker DeBakey Clinical Research Award will be shared by Brian Druker, Nicholas Lydon,...
In one of the most exciting historical moments for biomedical research, the Karolinska Institute of ...
Recent advances in cancer immunotherapy have directly built on 50 years of fundamental and technolog...
The first Tang Prize for Biopharmaceutical Science has been awarded to Prof. James P. Allison and Pr...
Michael R Shurin1,21Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA...
Research in two fronts has enabled the development of therapies that provide significant benefit to ...
The role of immune checkpoints in modulating the magnitude as well as the functional profile of T ce...
Immunotherapy with immune checkpoint inhibitors has emerged as the most significant advance in the ...
The immune system is the hard-wired host defense mechanism against pathogens as well as cancer. Five...
This editorial is published on the occasion of World Cancer day - February 4, 2022.Cancer immunother...
Given the high, and rapidly increasing, incidence of cancer coupled with the enormous cost burden as...
Abstract The immune system is the hard-wired host defense mechanism against pathogens as well as can...
Immune checkpoints blockade (ICB) has made revolutionary progress in cancer therapy recently. The de...
The past few years have witnessed something of a renaissance in the field of cancer immunotherapy, r...
Tumor immunotherapy has come to the fore fuelled by impressive clinical responses to checkpoint inhi...
This year the Lasker DeBakey Clinical Research Award will be shared by Brian Druker, Nicholas Lydon,...
In one of the most exciting historical moments for biomedical research, the Karolinska Institute of ...
Recent advances in cancer immunotherapy have directly built on 50 years of fundamental and technolog...
The first Tang Prize for Biopharmaceutical Science has been awarded to Prof. James P. Allison and Pr...
Michael R Shurin1,21Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA...
Research in two fronts has enabled the development of therapies that provide significant benefit to ...
The role of immune checkpoints in modulating the magnitude as well as the functional profile of T ce...
Immunotherapy with immune checkpoint inhibitors has emerged as the most significant advance in the ...
The immune system is the hard-wired host defense mechanism against pathogens as well as cancer. Five...
This editorial is published on the occasion of World Cancer day - February 4, 2022.Cancer immunother...
Given the high, and rapidly increasing, incidence of cancer coupled with the enormous cost burden as...
Abstract The immune system is the hard-wired host defense mechanism against pathogens as well as can...
Immune checkpoints blockade (ICB) has made revolutionary progress in cancer therapy recently. The de...
The past few years have witnessed something of a renaissance in the field of cancer immunotherapy, r...
Tumor immunotherapy has come to the fore fuelled by impressive clinical responses to checkpoint inhi...
DOI
Add to ORKG